{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:01:40Z","timestamp":1775545300334,"version":"3.50.1"},"reference-count":46,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMJ"],"DOI":"10.4274\/mmj.galenos.2025.44045","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:17:01Z","timestamp":1767165421000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety Profile of Roxadustat in Anemic Patients: A Meta-Analysis of 21 RCTs"],"prefix":"10.4274","author":[{"given":"Lokman Hekim","family":"TANRIVERDI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"SARICI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"ERKURT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hac\u0131 Bayram","family":"BERKTAS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"Lopez","year":"2016","unstructured":"1. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387:907-16.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: Core Curriculum 2018","volume":"71","author":"Fishbane","year":"2018","unstructured":"2. Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: Core Curriculum 2018. Am J Kidney Dis. 2018;71:423-35.","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000496492","article-title":"Iron deficiency anemia in chronic kidney disease","volume":"142","author":"Gafter-Gvili","year":"2019","unstructured":"3. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol. 2019;142:44-50.","journal-title":"Acta Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","unstructured":"4. Bhandari S, Spencer S, Oliveira B, et al. UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease. BMC Nephrol. 2025;26:193.","journal-title":"BMC Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5455\/annalsmedres.2023.12.337","article-title":"Efficacy and safety of molidustat for the anemia of chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Tanriverdi","year":"2024","unstructured":"5. Tanriverdi LH, Tay M, Sarici A. Efficacy and safety of molidustat for the anemia of chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Annals of Medical Research. 2024;31:177-84.","journal-title":"Annals of Medical Research"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Natale P, Palmer SC, Jaure A, et al. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022;8:CD013751.","DOI":"10.1002\/14651858.CD013751.pub2"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14656566.2024.2378903","article-title":"A spotlight on using HIF-PH inhibitors in renal anemia","volume":"25","author":"Odawara","year":"2024","unstructured":"7. Odawara M, Nishi H, Nangaku M. A spotlight on using HIF-PH inhibitors in renal anemia. Expert Opin Pharmacother. 2024;25:1291-9.","journal-title":"Expert Opin Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/MS9.0000000000002951","article-title":"Revolutionizing anemia management in dialysis: unveiling the potential of FDA-approved Vadadustat for chronic kidney disease (CKD) patients","volume":"87","author":"Gul","year":"2025","unstructured":"8. Gul MH, Waheed A, Jha M, Wardak AB, Ilma B, Khan U. Revolutionizing anemia management in dialysis: unveiling the potential of FDA-approved Vadadustat for chronic kidney disease (CKD) patients. Ann Med Surg (Lond). 2025;87:1094-6.","journal-title":"Ann Med Surg (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000536039","article-title":"Stabilizing hypoxia-inducible factor to manage anemia in chronic kidney disease: from basic theory to clinical study","volume":"10","author":"Wang","year":"2024","unstructured":"9. Wang Y, Yu X. Stabilizing hypoxia-inducible factor to manage anemia in chronic kidney disease: from basic theory to clinical study. Kidney Dis (Basel). 2024;10:132-42.","journal-title":"Kidney Dis (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Macdougall IC. Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime? Curr Opin Nephrol Hypertens. 2022;31:399-405.","DOI":"10.1097\/MNH.0000000000000813"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bi-as in randomised trials. BMJ. 2019;366:l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP","year":"2002","unstructured":"12. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.","journal-title":"Stat Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in sys-tematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","unstructured":"13. Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in sys-tematic reviews: a tutorial. Clinical Epidemiology and Global Health. 2019;7:192-8.","journal-title":"Clinical Epidemiology and Global Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting sys-tematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","unstructured":"14. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting sys-tematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-12.","journal-title":"J Clin Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","unstructured":"15. Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019;36:1438-54.","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ekir.2021.04.003","article-title":"Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD","volume":"6","author":"Akizawa","year":"2021","unstructured":"16. Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep. 2021;6:1810-28.","journal-title":"Kidney Int Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, Random-ized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadu-stat in CKD Patients with Anemia on Hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","unstructured":"17. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, Random-ized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadu-stat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol. 2020;31:1628-39.","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","unstructured":"18. Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36:1616-28.","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","unstructured":"19. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665-73.","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","unstructured":"20. Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6:1829-39.","journal-title":"Kidney Int Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients under-going long-term dialysis","volume":"381","author":"Chen","year":"2019","unstructured":"21. Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients under-going long-term dialysis. N Engl J Med. 2019;381:1011-22.","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney dis-ease not receiving dialysis","volume":"381","author":"Chen","year":"2019","unstructured":"22. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney dis-ease not receiving dialysis. N Engl J Med. 2019;381:1001-10.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","unstructured":"23. Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32:1373-86.","journal-title":"Nephrol Dial Transplant"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","unstructured":"24. Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2020;6:624-35.","journal-title":"Kidney Int Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stabledialysis: a europe-an phase 3, randomized, open-label,active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","unstructured":"25. Csiky B, Sch\u00f6mig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stabledialysis: a europe-an phase 3, randomized, open-label,active-controlled study (PYRENEES). Adv Ther. 2021;38:5361-80.","journal-title":"Adv Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","unstructured":"26. Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33:850-66.","journal-title":"J Am Soc Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in pa-tients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry","year":"2022","unstructured":"27. Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in pa-tients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022;97:174-84.","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ekir.2024.04.021","article-title":"The efficacy and safety of roxadustat for the treat-ment of posttransplantation anemia: a randomized study","volume":"9","author":"Kong","year":"2024","unstructured":"28. Kong W, Wu X, Shen Z, et al. The efficacy and safety of roxadustat for the treat-ment of posttransplantation anemia: a randomized study. Kidney Int Rep. 2024;9:1705-17.","journal-title":"Kidney Int Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open- label, active-comparator,dose-ranging, safety and exploratory efficacy study","volume":"67","author":"29","year":"2016","unstructured":"29. versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open- label, active-comparator,dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912-24.","journal-title":"Am J Kidney Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","unstructured":"30. Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36:1717-30.","journal-title":"Nephrol Dial Transplant"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, dou-ble-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","unstructured":"31. Shutov E, Su\u0142owicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, dou-ble-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021;36:1629-39.","journal-title":"Nephrol Dial Transplant"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Tan W, Wang X, Sun Y, et al. Roxadustat reduces left ventricular mass index com-pared to rHuEPO in haemodialysis patients in a randomized controlled trial. J In-tern Med. 2024;295:620-33.","DOI":"10.1111\/joim.13770"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating ane-mia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","unstructured":"33. Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating ane-mia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32:737-55.","journal-title":"J Am Soc Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal di-alysis patients: a randomized controlled trial","volume":"121","author":"Hou","year":"2022","unstructured":"34. Hou YP, Mao XY, Wang C, et al. Roxadustat treatment for anemia in peritoneal di-alysis patients: a randomized controlled trial. J Formos Med Assoc. 2022;121:529-38.","journal-title":"J Formos Med Assoc"},{"key":"ref34","unstructured":"35. US Food & Drug Administration. Cardiovascular and Renal Drugs Advisory Com-mittee. [ Jul; 2021]; https:\/\/www.fda.gov\/advisory-committees\/human-drug-advisory-committees\/cardiovascular-and-renal-drugs-advisory-committee URL: https:\/\/www.fda.gov\/media\/150728\/download.; 2021."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40620-023-01849-9","article-title":"A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat","volume":"37","author":"Locatelli","year":"2024","unstructured":"36. Locatelli F, Ravera M, Esposito C, Grandaliano G, Gesualdo L, Minutolo R. A novel scenario in the therapeutic management of anemia of chronic kidney disease: placement and use of roxadustat. J Nephrol. 2024;37:1107-19.","journal-title":"J Nephrol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2195011","DOI":"10.1080\/0886022X.2023.2195011","article-title":"The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Zhou","year":"2023","unstructured":"37. Zhou Q, Mao M, Li J, Deng F. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2023;45:2195011.","journal-title":"Ren Fail"},{"key":"ref37","unstructured":"38. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospec-tive studies of disease. J Natl Cancer Inst. 1959;22:719-48."},{"key":"ref38","unstructured":"39. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Cochrane Handbok for Systematic Reviews of Interventions. Version 6.4 (Updated August 2023). Cochrane, 2023. 2024."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2313864","DOI":"10.1080\/0886022X.2024.2313864","article-title":"Cardiovascular and renal safety outcomes of hypox-ia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis","volume":"46","author":"Tian","year":"2024","unstructured":"40. Tian L, Wang M, Liu M, et al. Cardiovascular and renal safety outcomes of hypox-ia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024;46:2313864.","journal-title":"Ren Fail"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.jfma.2022.06.008","article-title":"Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease pa-tients: a meta-analysis","volume":"121","author":"Hou","year":"2022","unstructured":"41. Hou YP, Wang C, Mao XY, Zhang MZ, Li B. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease pa-tients: a meta-analysis. J Formos Med Assoc. 2022;121:2288-99.","journal-title":"J Formos Med Assoc"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"17914","DOI":"10.18632\/aging.203143","article-title":"Roxadustat for the treatment of anemia in pa-tients with chronic kidney diseases: a meta-analysis","volume":"13","author":"Zhang","year":"2021","unstructured":"42. Zhang L, Hou J, Li J, Su SS, Xue S. Roxadustat for the treatment of anemia in pa-tients with chronic kidney diseases: a meta-analysis. Aging (Albany NY). 2021;13:17914-29.","journal-title":"Aging (Albany NY)"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2413176","DOI":"10.1155\/2022\/2413176","article-title":"Efficacy and safety of roxadustat in patients with chronic kid-ney disease: an updated meta-analysis of randomized controlled trials including 6,518 patients","volume":"2022","author":"Lei","year":"2022","unstructured":"43. Lei J, Li H, Wang S. Efficacy and safety of roxadustat in patients with chronic kid-ney disease: an updated meta-analysis of randomized controlled trials including 6,518 patients. Biomed Res Int. 2022;2022:2413176.","journal-title":"Biomed Res Int"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.phrs.2020.104747","article-title":"Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney dis-ease patients: a systematic review and meta-analysis","volume":"155","author":"Liu","year":"2020","unstructured":"44. Liu J, Zhang A, Hayden JC, et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney dis-ease patients: a systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.","journal-title":"Pharmacol Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1380326","DOI":"10.3389\/fphar.2024.1380326","article-title":"Assessment of the safety of Roxadustat for cardiovascu-lar events in chronic kidney disease-related anemia using meta-analysis and bio-informatics","volume":"15","author":"Li","year":"2024","unstructured":"45. Li X, Jiang S, Gu X, et al. Assessment of the safety of Roxadustat for cardiovascu-lar events in chronic kidney disease-related anemia using meta-analysis and bio-informatics. Front Pharmacol. 2024;15:1380326.","journal-title":"Front Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","unstructured":"46. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998;316:61-6.","journal-title":"BMJ"}],"container-title":["Medeniyet Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:04:24Z","timestamp":1775541864000},"score":1,"resource":{"primary":{"URL":"https:\/\/medeniyetmedicaljournal.org\/articles\/doi\/MMJ.galenos.2025.44045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":46,"URL":"https:\/\/doi.org\/10.4274\/mmj.galenos.2025.44045","relation":{},"ISSN":["2149-2042"],"issn-type":[{"value":"2149-2042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}